GLX Analytix provides a clinical‑stage blood test that measures disease‑specific fragments of the vascular glycocalyx and uses AI/ML to generate a GLX Signature reflecting brain microvascular health. The low‑cost, scalable assay delivers an actionable report for diagnosing, monitoring, and guiding treatment decisions in neuropsychiatric, neurodegenerative, and autoimmune brain disorders.
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnosis and monitoring of neuropsychiatric, neurodegenerative, and autoimmune brain diseases rely on invasive procedures, expensive imaging, or indirect clinical assessments, leading to delayed detection and limited ability to track disease progression accurately.
Solution
GLX Analytix offers a clinical‑stage blood test that quantifies disease‑specific fragments of the vascular glycocalyx shed into circulation. Using a patented assay combined with machine‑learning algorithms, the platform generates a GLX Signature that reflects the state of the brain’s microvascular health. The test is low‑cost, scalable, and can be performed from a standard blood draw, providing clinicians with an actionable report to support diagnosis, monitor treatment response, and inform personalized therapeutic decisions across a range of brain disorders.
Target Audience
Primary customers are neurologists, psychiatrists, and other clinicians managing neurodegenerative, neuropsychiatric, and autoimmune brain disorders, as well as pharmaceutical companies developing disease‑modifying therapies.
Features
- Patented assay that isolates and measures glycocalyx fragments from a routine blood sample
- AI/ML pipeline that translates glycocalyx measurements into a disease‑specific GLX Signature
- Automated, cloud‑based analytics delivering a concise, actionable report for clinicians
- Proven applicability to stroke recovery, schizophrenia severity, Parkinson’s disease progression, and multiple sclerosis biomarkers
- Scalable, low‑cost workflow suitable for high‑throughput clinical laboratories